Fundamental Analysis of YUMANITY THERAPEUTICS INC(NASDAQ:YMTX) stock

Fundamental Rating

Taking everything into account, YMTX scores 1 out of 10 in our fundamental rating. YMTX was compared to 586 industry peers in the Biotechnology industry. The financial health of YMTX is average, but there are quite some concerns on its profitability. YMTX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year YMTX has reported negative net income.

In the past year YMTX has reported a negative cash flow from operations.

YMTX had negative earnings in each of the past 5 years.

YMTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for YMTX are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

YMTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

YMTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for YMTX has been increased compared to 1 year ago.

The debt/assets ratio for YMTX is higher compared to a year ago.

2.2 Solvency

YMTX has an Altman-Z score of -35.79. This is a bad value and indicates that YMTX is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of YMTX (-35.79) is worse than 94.38% of its industry peers.

There is no outstanding debt for YMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-35.79

ROIC/WACCN/A

WACC9.55%

2.3 Liquidity

YMTX has a Current Ratio of 2.21. This indicates that YMTX is financially healthy and has no problem in meeting its short term obligations.

YMTX has a Current ratio of 2.21. This is amonst the worse of the industry: YMTX underperforms 80.97% of its industry peers.

A Quick Ratio of 2.21 indicates that YMTX has no problem at all paying its short term obligations.

With a Quick ratio value of 2.21, YMTX is not doing good in the industry: 79.25% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.21
Quick Ratio	2.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for YMTX have decreased strongly by -337.84% in the last year.

The Revenue for YMTX has decreased by -65.84% in the past year. This is quite bad

YMTX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.82% yearly.

EPS 1Y (TTM)-337.84%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q68.04%

Revenue 1Y (TTM)-65.84%

Revenue growth 3Y41.49%

Revenue growth 5Y-0.82%

Revenue growth Q2Q-14.25%

3.2 Future

The Earnings Per Share is expected to grow by 4.21% on average over the next years.

The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad

EPS Next Y-60.56%

EPS Next 2Y-59.53%

EPS Next 3Y-27.59%

EPS Next 5Y4.21%

Revenue Next Year9.96%

Revenue Next 2Y14.87%

Revenue Next 3Y-25.99%

Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

YMTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year YMTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as YMTX's earnings are expected to decrease with -27.59% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-59.53%

EPS Next 3Y-27.59%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for YMTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

YUMANITY THERAPEUTICS INC

NASDAQ:YMTX (12/16/2022, 7:00:02 PM)

After market: 1.9 +0.01 (+0.53%)

1.89

+0.15 (+8.62%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap20.52M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.51

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.21
Quick Ratio	2.21
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-337.84%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-60.56%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-65.84%

Revenue growth 3Y41.49%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

YUMANITY THERAPEUTICS INC (YMTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens